Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

JIANG Qi; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2015.02.019

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 33 Issue 2

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2015 > 33(2): 163-166,182

JIANG Qi, QIAN Qijun. Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 163-166,182. doi: 10.3969/j.issn.1006-0111.2015.02.019

Citation:

JIANG Qi, QIAN Qijun. Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 163-166,182. doi: 10.3969/j.issn.1006-0111.2015.02.019

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

doi: 10.3969/j.issn.1006-0111.2015.02.019

Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

Received Date: 2014-12-18
Rev Recd Date: 2015-01-26

Abstract

Cancer-induced immunosuppressive cells play an important immunosuppressive role during the tumor development process, and the development and progression of tumors are always accompanied with abnormal accumulation of cancer-induced immunosuppressive cells. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC) are major components of these inhibitory cellular networks, and they can inhibit antitumor immune response through multiple mechanisms. Recent studies have provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, some conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced anti-tumor immunity. Hence, chemotherapeutics, used as a preconditioning regimen and combined with subsequent immunotherapy, can promote anti-tumor immune response. Anticancer chemoimmunotherapy strategy will change the recognization of the role for conventional chemotherapy in anticancer treatment, and it will be helpful to optimize the chemotherapy strategies more reasonably.
- chemotherapeutics,
- regulatory T cell,
- myeloid-derived suppressor cell,
- chemoimmunotherapy,
- cancer-induced immunosuppressive cell

References

[1]	Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer[J].Clin Genitourin Cancer,2006,5(3),206-211.
[2]	Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion[J]. Nat Rev Immunol,2006,6(10):715-727.
[3]	Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009,9(3):162-174.
[4]	Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy[J]. Nat Rev Cancer,2007,7(11):880-887.
[5]	Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat Med,2004,10(9):942-949.
[6]	Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol,1995,155(3):1151-1164.
[7]	曾益新,吕有勇,朱明华,等.肿瘤学[M].3版. 北京:人民卫生出版社,2012:281-282.
[8]	North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells[J]. J Exp Med,1982,155(4):1063-1074.
[9]	Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy[J]. Adv Cancer Res,2010,107:1-37.
[10]	Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model[J]. Cancer Res,2009,69(10):4309-4318.
[11]	Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative[J]. Eur J Immunol,2004,34(2):336-344.
[12]	Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity[J]. Cancer Immunol Immunother,2013,62(2):203-216.
[13]	Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy?[J]. Br J Cancer,2009,100(11):1697-1703.
[14]	Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother,2007,56(5):641-648.
[15]	Zhang L,Dermawan K,Jin M,et al.Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy[J].Clin Immunol,2008,129(2):219-229.
[16]	Liu N, Zheng Y, Zhu Y, et al. Selective impairment of CD4+CD25+Foxp3⁽⁺⁾ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis[J]. Int mmunopharmacol,2011,11(2):212-219.
[17]	Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement[J]. Clin Cancer Res,2008,14(11):3536-3544.
[18]	Reinartz S, Pfisterer J, du Bois A, et al. Suppressive activity rather than frequency of FoxP3⁽⁺⁾ regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment[J]. Hum Immunol,2010,71(1):36-44.
[19]	Banissi C, Ghiringhelli F, Chen L, et al. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model[J]. Cancer Immunol Immunother,2009,58(10):1627-1634.
[20]	Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25+Foxp3⁽⁺⁾ regulatory T-cells in advanced melanoma patients[J]. J Transl Med,2013,11:135.
[21]	Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients[J]. J Clin Oncol,2005,23(35):8950-8958.
[22]	Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells[J]. Cancer Immunol Immunother,2009,58(7):1033-1045.
[23]	Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer[J]. J Immunol,2009,182(8):4499-4506.
[24]	Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J]. Cancer Res,2010,70(8):3052-3061.
[25]	Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers[J]. Clin Cancer Res,2010,16(18):4583-4594.
[26]	Kodumudi KN, Weber A, Sarnaik AA, et al. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma[J]. J Immunol,2012,189(11):5147-5154.
[27]	Michels T, Shurin GV, Naiditch H, et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner[J]. J Immunotoxicol,2012,9(3):292-300.
[28]	Alizadeh D, Trad M, Hanke NT, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J]. Cancer Res,2014,74(1):104-118.
[29]	Mikysková R, Indrová M, Vlková V, et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment[J]. J Leukoc Biol,2014,95(5):743-753.
[30]	Mikysková R, Indrová M, Pollaková V, et al. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors[J]. J Immunother,2012,35(5):374-384.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3199) PDF downloads(593) Cited by()

Proportional views

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

Received Date: 2014-12-18

Rev Recd Date: 2015-01-26

Key words:

Abstract: Cancer-induced immunosuppressive cells play an important immunosuppressive role during the tumor development process, and the development and progression of tumors are always accompanied with abnormal accumulation of cancer-induced immunosuppressive cells. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC) are major components of these inhibitory cellular networks, and they can inhibit antitumor immune response through multiple mechanisms. Recent studies have provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, some conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced anti-tumor immunity. Hence, chemotherapeutics, used as a preconditioning regimen and combined with subsequent immunotherapy, can promote anti-tumor immune response. Anticancer chemoimmunotherapy strategy will change the recognization of the role for conventional chemotherapy in anticancer treatment, and it will be helpful to optimize the chemotherapy strategies more reasonably.

HTML

Reference (30)

[1]	Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer[J].Clin Genitourin Cancer,2006,5(3),206-211.
[2]	Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion[J]. Nat Rev Immunol,2006,6(10):715-727.
[3]	Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009,9(3):162-174.
[4]	Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy[J]. Nat Rev Cancer,2007,7(11):880-887.
[5]	Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat Med,2004,10(9):942-949.
[6]	Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol,1995,155(3):1151-1164.
[7]	曾益新,吕有勇,朱明华,等.肿瘤学[M].3版. 北京:人民卫生出版社,2012:281-282.
[8]	North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells[J]. J Exp Med,1982,155(4):1063-1074.
[9]	Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy[J]. Adv Cancer Res,2010,107:1-37.
[10]	Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model[J]. Cancer Res,2009,69(10):4309-4318.
[11]	Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative[J]. Eur J Immunol,2004,34(2):336-344.
[12]	Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity[J]. Cancer Immunol Immunother,2013,62(2):203-216.
[13]	Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy?[J]. Br J Cancer,2009,100(11):1697-1703.
[14]	Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother,2007,56(5):641-648.
[15]	Zhang L,Dermawan K,Jin M,et al.Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy[J].Clin Immunol,2008,129(2):219-229.
[16]	Liu N, Zheng Y, Zhu Y, et al. Selective impairment of CD4+CD25+Foxp3⁽⁺⁾ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis[J]. Int mmunopharmacol,2011,11(2):212-219.
[17]	Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement[J]. Clin Cancer Res,2008,14(11):3536-3544.
[18]	Reinartz S, Pfisterer J, du Bois A, et al. Suppressive activity rather than frequency of FoxP3⁽⁺⁾ regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment[J]. Hum Immunol,2010,71(1):36-44.
[19]	Banissi C, Ghiringhelli F, Chen L, et al. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model[J]. Cancer Immunol Immunother,2009,58(10):1627-1634.
[20]	Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25+Foxp3⁽⁺⁾ regulatory T-cells in advanced melanoma patients[J]. J Transl Med,2013,11:135.
[21]	Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients[J]. J Clin Oncol,2005,23(35):8950-8958.
[22]	Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells[J]. Cancer Immunol Immunother,2009,58(7):1033-1045.
[23]	Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer[J]. J Immunol,2009,182(8):4499-4506.
[24]	Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J]. Cancer Res,2010,70(8):3052-3061.
[25]	Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers[J]. Clin Cancer Res,2010,16(18):4583-4594.
[26]	Kodumudi KN, Weber A, Sarnaik AA, et al. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma[J]. J Immunol,2012,189(11):5147-5154.
[27]	Michels T, Shurin GV, Naiditch H, et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner[J]. J Immunotoxicol,2012,9(3):292-300.
[28]	Alizadeh D, Trad M, Hanke NT, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J]. Cancer Res,2014,74(1):104-118.
[29]	Mikysková R, Indrová M, Vlková V, et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment[J]. J Leukoc Biol,2014,95(5):743-753.
[30]	Mikysková R, Indrová M, Pollaková V, et al. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors[J]. J Immunother,2012,35(5):374-384.

Message Board

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

doi: 10.3969/j.issn.1006-0111.2015.02.019

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views